One in six hospital beds filled by dementia patients
One in six UK hospital beds is currently occupied by a person with dementia, at a cost to the taxpayer of £2.8 billion annually, with this number set… read more.
One in six UK hospital beds is currently occupied by a person with dementia, at a cost to the taxpayer of £2.8 billion annually, with this number set… read more.
Pregnant women in Australia are facing an unfair two-tiered system for managing morning sickness, with financial status impacting who can access the full range of modern anti-nausea medications… read more.
The Medicines and Healthcare products Regulatory Agency (MHRA) authorised orforglipron (Foundayo), making the UK the first country in Europe to approve this GLP-1 tablet for weight management and type 2 diabetes. Alongside a reduced-calorie diet and increased… read more.
Outlook Therapeutics, Inc. announced that the FDA has approved Lytenava (bevacizumab-vikg) for the treatment of neovascular age-related macular degeneration (nAMD), commonly known as wet AMD. The approval establishes… read more.
According to the Medicines and Healthcare products Regulatory Agency (MHRA) website, an intravesical delivery system containing gemcitabine (Inqlexzo) has been authorised for the treatment of adults for certain… read more.
Moderna, Inc. announced that the FDA has approved Mflusiva (mRNA-1010), a new vaccine against seasonal influenza, for use in all adults 50 years and older. This approval follows… read more.
GE HealthCare announced the launch of Invenia Abus (Automated Breast Ultrasound) Prime and Abus StreamVue, a redesigned enterprise viewer that recently received FDA 510(k) clearance and CE Marking,… read more.
Arcutis Biotherapeutics announced that the FDA has approved the supplemental New Drug Application (sNDA) to expand the indication for Zoryve (roflumilast) cream 0.3% for the topical treatment of… read more.
Genmab A/S announced that the European Commission (EC) granted marketing authorization for Tepkinly (epcoritamab) in combination with lenalidomide and rituximab (Tepkinly + R2) for the treatment of adult… read more.
New peer-reviewed publications find significant gaps in lip product regulation and safety testing, including reliance on inappropriate skin models and significant underestimation of usage and ingestion rates, leaving… read more.
Letters to patients from ophthalmology services—-the highest volume outpatient specialty in UK healthcare—include too much complex language and medical terminology which patients are likely to find hard to… read more.
Novartis announced the FDA approved Pluvicto (lutetium Lu 177 vipivotide tetraxetan) in combination with an androgen receptor pathway inhibitor (ARPI) for patients with prostate-specific membrane antigen (PSMA)-positive metastatic… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.